Medtronic plc (NYSE:MDT) Bank of America Global Healthcare Conference 2022 September 15, 2022 9:10 AM ET Company Participants Rob ten Hoedt - Executive Vice President & President EMEA & APAC Conference Call Participants Travis Steed - Bank of America Rob ten Hoedt [Call Starts Abruptly] That is the de novo patients plus the deferred patients should all be treated, then we're going to get this increase in productivity. That happened in Spain and Italy but it didn't in France, in the UK and in Germany. So th ...

Medtronic plc (NYSE:MDT) Conference Call Summary Industry Overview - The conference was part of the Morgan Stanley 20th Annual Global Healthcare Conference held on September 12, 2022, focusing on the medical technology sector, specifically Medtronic plc. Key Points and Arguments Market Dynamics - Staffing issues in the healthcare sector are improving, nearing pre-pandemic levels for most procedures, although some areas still lag behind [3][4] - Supply chain challenges, particularly with plastics, resins, and semiconductors, are showing signs of improvement, although semiconductor issues may persist longer [3][4] Capital and Revenue - Capital expenditure remains a small portion of revenue, tied to profitable procedures, with a healthy capital environment observed [6] - Medtronic is focusing on capital allocation to higher growth areas across its 20 operating units [8] Business Optimization - The company is decentralizing operations to enhance innovation and performance accountability, which has exceeded expectations [10] - Medtronic is leveraging its scale by focusing on strategic customers, technology platforms, and centralizing its supply chain [12] Direct-to-Consumer (DTC) Strategy - Medtronic is shifting towards a consumer-focused approach, particularly in diabetes and renal denervation (RDN) markets, to drive patient awareness and engagement [17][18] M&A and Portfolio Management - The company is actively managing its portfolio through acquisitions and divestitures, focusing on higher growth segments and optimizing capital allocation [20][21] - Recent acquisitions, such as Affera, are aimed at enhancing Medtronic's cardiac ablation solutions [22][23] Research and Development Focus - Key areas of investment include robotics (HUGO), atrial fibrillation (AFIB), structural heart, and diabetes, with a focus on innovative solutions and market leadership [25][26] Pricing Power and Inflation - Medtronic is experiencing a shift towards positive pricing power, with efforts to manage costs and improve margins despite inflationary pressures [34][36] Product Development and Ecosystem - The company is enhancing its surgical robotics ecosystem, focusing on integrating digital surgery platforms and improving the overall offering [42][45] Sales Strategy and Market Rollout - Medtronic plans to leverage its existing interventional cardiology sales force for the rollout of new products, ensuring efficient training and integration into current operations [50][51] Additional Important Insights - The company is focusing on building a more performance-based culture through revised incentives tied to growth and market share [10] - Medtronic is exploring creative structures for venture investments to mitigate risks associated with new acquisitions [22] - The company is committed to reducing the number of suppliers to enhance cost efficiency in its supply chain [36] This summary encapsulates the key discussions and strategic directions outlined during the conference call, highlighting Medtronic's focus on innovation, market dynamics, and operational efficiency in the medical technology sector.

Medtronic plc (NYSE:MDT) 2022 Wells Fargo Healthcare Conference Call September 7, 2022 11:35 AM ET Company Participants Karen Parkhill - Executive Vice President and Chief Financial Officer Gregory Hertz - Senior Director of Investor Relations Conference Call Participants Lawrence Biegelsen - Wells Fargo Securities, LLC Lawrence Biegelsen All right. Good morning. I'm Larry Biegelsen, the Medical Device analyst at Wells Fargo. And it's my pleasure to host this session with Medtronic. With us we have, Karen P ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 29, 2022 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from __________ to __________ Commission File Number 001-36820 ® Medtronic plc (Exact name of registrant as specified in its charter) Ireland 98-1183488 (State of incorporation) (I.R.S. ...

Medtronic plc (NYSE:MDT) Q1 2023 Earnings Conference Call August 23, 2022 8:00 AM ET Company Participants Ryan Weispfenning - VP and Head, IR Geoff Martha - Chairman and CEO Karen Parkhill - CFO Sean Salmon - EVP and President, Cardiovascular Portfolio Bob White - EVP and President, Medical Surgical Portfolio Brett Wall - EVP and President, Neuroscience Portfolio Que Dallara - EVP and President, Diabetes Operating Unit Conference Call Participants Robbie Marcus - JPMorgan Vijay Kumar - Evercore ISI Travis S ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended April 29, 2022. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from __________ to __________ Commission File No. 1-36820 ® Medtronic plc (Exact name of registrant as specified in its charter) Ireland 98-1183488 (State or other ...

Medtronic plc (NYSE:MDT) Conference Call Summary Company Overview - **Company**: Medtronic plc - **Event**: Goldman Sachs Global Healthcare Conference Call - **Date**: June 14, 2022 - **Participants**: Geoff Martha (Chairman & CEO), Amit Hazan (Goldman Sachs Medical Technology Analyst) Key Points Industry Context - The healthcare industry, particularly medical technology, has faced significant challenges due to COVID-19 and supply chain disruptions [4][5][6] - Medtronic has played a critical role in responding to the pandemic, particularly with ventilators [4] Supply Chain Challenges - Medtronic experienced acute supply chain issues, particularly with semi chips and resins affecting their Energy business and packaging [7][8] - A supplier explosion caused significant disruptions in the Surgical Innovations business [8] - Supply chain issues are expected to improve, particularly in the second half of the fiscal year [9] - The company is implementing structural changes to enhance supply chain resiliency, moving from a fragmented approach to a centralized model [11][12][14] Financial Guidance and Revenue Expectations - Medtronic is guiding for 4% to 5% revenue growth for the fiscal year, despite challenges in the previous quarters [22][24] - The company anticipates easier comparisons in the second half of the fiscal year due to lower bases from the previous year [25] - Key product launches are expected to drive growth, including new TAVR and EV ICD products [26] Research and Development (R&D) - Medtronic aims to increase R&D spending to outpace sales growth, focusing on higher-growth opportunities [28] - The company is committed to improving R&D productivity and has streamlined operations to allow for increased investment [29] Operating Margins - Medtronic is targeting a return to pre-COVID operating margins of around 28% [30][32] - The company is focused on achieving 5% top-line growth and 8% EPS growth, alongside a growing dividend [32][33] Product Development and Market Position - The surgical robot is expected to see significant growth, with positive feedback from international markets [34][36] - Medtronic is optimistic about the diabetes segment, with the 780G system showing promising results in trials [41][43] - The company is also focused on the renal denervation (RDN) market, with ongoing trials expected to yield positive results [48][49] Market Dynamics in China - Short-term challenges include navigating COVID lockdowns and pricing pressures, but long-term growth in China is still anticipated [53][54] - Medtronic acknowledges increased risks in the Chinese market due to geopolitical factors but remains bullish on investment opportunities [55] Capital Allocation and Portfolio Management - Medtronic is conducting a deep dive into its portfolio to ensure capital is allocated to higher-growth areas [57] - Ongoing evaluations may lead to divestitures or restructuring within the portfolio [57] Additional Insights - The company is adapting to a new normal in supply chain management, balancing efficiency with resiliency [11][14] - Medtronic's strategy includes leveraging acquisitions and partnerships to enhance R&D capabilities [29] - The focus on integrated insulin delivery systems positions Medtronic favorably in the diabetes market [44][46] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Medtronic's response to current challenges and its plans for future growth.